Recruiting soon

L-Arginine Therapy Benefits for Heart Failure Patients

Study Aim

This phase 2 study aims to evaluate the benefits of L-Arginine therapy on heart function, specifically measuring changes in global longitudinal strain value (GLS), in patients with heart failure.

What is being tested

L-Arginine Powder

+ Placebo

Drug

Who is being recruted

Cardiovascular Diseases

+ Heart Diseases

+ Heart Failure

Over 19 Years

+10 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-ControlledPhase 2

Interventional

Study Start: February 2026

See protocol details

Summary

Principal SponsorGerman University in Cairo

Study ContactSara Araby, MscMore contacts

Last updated: February 7, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2026

Actual date on which the first participant was enrolled.

Heart failure poses a significant global challenge, with various treatment strategies available. This study focuses on patients with an ejection fraction below 40%, a measure indicating a reduced ability of the heart to pump blood effectively. The research explores the potential benefits and side effects of L-Arginine, an amino acid known to have positive effects on blood vessels, when added to existing treatments for heart failure patients. The goal is to determine if L-Arginine can enhance the effectiveness of current treatments and improve patient outcomes. During the study, participants receive L-Arginine as an add-on to their current treatment regimen. The primary method of evaluating the treatment's effectiveness involves measuring changes in the Global Longitudinal Strain (GLS) value of the heart from the baseline. GLS is a measure of the heart's mechanical efficiency. By tracking these changes, researchers aim to understand if L-Arginine can improve heart function in patients with heart failure.

Official TitleEffect of Add-on L-Arginine Therapy on Clinical Outcome of Heart Failure Patients: A Randomized- Controlled Trial

NCT07394270

Principal SponsorGerman University in Cairo

Study ContactSara Araby, MscMore contacts

Last updated: February 7, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

200 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 19 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesHeart DiseasesHeart Failure

Criteria

4 inclusion criteria required to participate

Stable patients

Capable and willing to provide written consent

eGFR >30 mL/min/1.73 m2

Patients with EF <40%

6 exclusion criteria prevent from participating

Patients with implantable cardioverter-defibrillator

Pregnant or lactating fmeales

Acute heart failure patients

Patients with a history of sensitivity to L-Arginine or any of the excipients

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator

Patients in this arm will be administered 6 gm L-arginine per day

Group II

Placebo

Patients in this arm will take 6 gm placebo per day

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Ain Shams University

Cairo, EgyptOpen Ain Shams University in Google Maps

Recruiting soonOne Study Center